|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00512 GRAND PHARMA
Nominal 
4.600 +0.040 (+0.877%) | 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Turnover | 10,529,590 | 10.116% | 9,562,285 | 8,597,975 | 6,352,919 | 6,590,635 |
| Cost of Sales | (4,005,524) | 10.932% | (3,610,806) | (3,350,737) | (2,317,725) | (2,549,270) |
| Gross Profit | 6,524,066 | 9.621% | 5,951,479 | 5,247,238 | 4,035,194 | 4,041,365 |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 18,763 | -- | (91,345) | (8,350) | 253,604 | (68,392) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (58,664) | -- | 23,017 | 484,495 | -- | -- | |
| Share of Results of Asso. & JCEs | (25,008) | -42.886% | (43,786) | 113,862 | 61,979 | 114,962 | |
| Profit / (Loss) before Taxation | 2,344,197 | -6.861% | 2,516,893 | 2,785,832 | 2,073,583 | 1,355,973 | |
| Taxation | (448,755) | 7.193% | (418,642) | (380,800) | (292,374) | (230,485) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (15,444) | -17.991% | (18,832) | (2,469) | 11,452 | 25,460 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,879,998 | -9.590% | 2,079,419 | 2,402,563 | 1,792,661 | 1,150,948 | |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Net Finance Costs / (Income) | 197,400 | 67.733% | 117,687 | 18,011 | 97,375 | 135,350 |
| Depreciation & Amortisation | 392,210 | -0.684% | 394,912 | 339,519 | 287,061 | 477,136 |
| Directors' Emoluments | 8,988 | 41.387% | 6,357 | 4,554 | 2,434 | 3,029 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 53.600 | -8.688% | 58.700 | 67.720 | 52.030 | 35.120 |
| DPS (cts) | 26.000 | -- | 14.000 | 11.000 | 11.000 | 9.600 |
| Dividend Payout Ratio (%) | 48.507% | -- | 23.850% | 16.243% | 21.142% | 27.335% |
| Cash flow per share ($) | 0.691 | -- | 0.520 | 0.565 | 0.423 | 0.398 |
| NBV per share ($) | 4.270 | -- | 3.984 | 3.773 | 3.166 | 2.480 |
| Remarks: | Real time quote last updated: 01/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 1,557,945 |
| %Change | 51.352% |
| EPS / (LPS) | HKD 0.444 |
| NBV Per Share ($) | HKD 4.428 |